JK
Therapeutic Areas
Septerna Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SEP-479 (PTH1R Agonist) | Hypoparathyroidism | Phase 2 |
| SEP-631 (MRGPRX2 NAM) | Chronic spontaneous urticaria and other mast cell diseases | Phase 2 |
| TSHR Program (TSHR NAM) | Graves' disease and Thyroid Eye Disease | Phase 1 |
| Metabolic Programs (GCGR + Undisclosed, GIPR, GLP-1R) | Obesity and other cardiometabolic diseases | Discovery |
| Undisclosed Partnered Program | Undisclosed | Discovery |
| Research Programs | Neurology, Women's Health, Cardiovascular Disease, Respiratory Disease | Discovery |
Leadership Team at Septerna
JF
Jeffrey Finer
Chief Executive Officer and Co-Founder
GL
Gil Labrucherie
Chief Financial Officer
LB
Liz Bhatt
President and Chief Operating Officer
MA
Mark A. Wilson
Chief Legal Officer
SS
Samira Shaikhly
Chief People Officer
UK
Uwe Klein
Senior Vice President, Biological Sciences
DL
Daniel Long
Senior Vice President, Drug Discovery
AE
Alan Ezekowitz
Director
JT
Jeffrey Tong
Chairman of the Board
AB
Abraham Bassan
Director